SFS
CLDX icon

Sowell Financial Services’s Celldex Therapeutics CLDX Stock Holding History

Sowell Financial Services’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-13
Closed – – 911
2021
Q1 		$0 Hold
13
– – ﹤0.01% 3125
2020
Q4 		$0 Sell
13
-200
-94% -$3.6K ﹤0.01% 2707
2020
Q3 		$3K Buy
213
+200
+1,538% +$2.34K ﹤0.01% 2109
2020
Q2 		$0 Hold
13
– – ﹤0.01% 2481
2020
Q1 		$0 Hold
13
– – ﹤0.01% 2451
2019
Q4 		$0 Hold
13
– – ﹤0.01% 2521
2019
Q3 		$0 Buy
+13
New +$30 ﹤0.01% 2393

Other funds holding CLDX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return

Sowell Financial Services's CLDX Position: Q2 2021 in Review

Sowell Financial Services sold out of Celldex Therapeutics (CLDX) in Q2 2021, closing a stake of 13 shares.

Sowell Financial Services first reported a position in CLDX in Q3 2019 and held it in 7 quarters. The position peaked at $3K in Q3 2020. 131 funds tracked by Wall St. Rank hold CLDX as of Q2 2021.

  • Sowell Financial Services reported no remaining Celldex Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Sowell Financial Services sold 13 Celldex Therapeutics shares in Q2 2021.
  • Sowell Financial Services first reported a position in Celldex Therapeutics in Q3 2019 and held it in 7 quarters.
  • Sowell Financial Services's Celldex Therapeutics position peaked at $3K in Q3 2020.
  • 131 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2021.

Based on Sowell Financial Services's 13F filing for Q2 2021, filed 5 Aug 2021.